Tumor Mutational Burden Testing on Biopsy Samples
Tumor mutational burden testing counts mutations in a cancer sample. Doctors use that count to judge how likely a tumor is to respond to immunotherapy. As a result, a small biopsy can guide a major treatment choice.
Tumor mutational burden, or TMB, measures how many mutations sit in the tumor genome. Labs usually report it as mutations per megabase. A higher score means the tumor has built more abnormal proteins. Therefore, the immune system has more targets to recognize.
Biopsy tissue supplies the DNA for this test. Pathologists first confirm that the sample contains enough tumor cells. Then the lab extracts DNA and sequences a large gene panel, or sometimes the whole exome. In addition, many labs sequence matched normal tissue so they can ignore inherited variants.
The count depends on the method. Panel size, variant filters, and the cutoff for a “high” score all change the result. Consequently, two labs can label the same tumor differently. Groups such as the Friends of Cancer Research have pushed for shared standards. Still, assay differences remain a practical limit.
High TMB often links to better response to immune checkpoint inhibitors. Tumors with many mutations tend to show more neoantigens. Those neoantigens can draw T cells into the tumor. However, TMB does not guarantee benefit. Some high-TMB cancers still fail treatment, and some low-TMB cancers still respond.
The test works best alongside other markers. Microsatellite instability, PD-L1 staining, and specific driver mutations add context. For example, a lung cancer sample may carry a high TMB and a targetable EGFR mutation. In that case, targeted therapy usually comes first. Therefore, TMB should not stand alone in the report.
Biopsy quality controls the result. A small or necrotic sample can undercount mutations. Low tumor fraction can also hide true variants. In addition, prior treatment can change the mutation load before the biopsy. Labs flag these limits so clinicians do not overread a weak sample.
TMB testing also supports research and trial entry. Many immunotherapy studies set a TMB threshold for eligibility. Serial biopsies can then show whether the mutation load falls after treatment. Meanwhile, blood-based TMB from circulating tumor DNA offers a less invasive option when tissue is scarce. Tissue testing remains the reference when the biopsy is adequate.
Tumor mutational burden testing turns a biopsy into a numeric clue about immune response. It works only when the sample, the assay, and the clinical context all align. Therefore, clear reporting and combined biomarker review matter as much as the mutation count itself.